Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Completed Journey
Companies On The Road
Follow The Artist
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Completed Journey
Companies We've Met
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
2021 Cell & Gene Therapy Report
2021 Monoclonal Antibody & Recombinant Protein Market Report
2022 Sterile Drug Market Report
2022 API Market Report
2022 OSD Market Report
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
Cancer
19 Articles Available
Can't find what you're looking for? Try our
advanced search
.
Immuno-Oncology
Targeted Immune System Activation: A Paradigm Shift in Immuno-oncology
PAO-12-022-CL-01
Phase I Trial
Anixa Biosciences Announces the Initiation of its Ovarian Cancer CAR-T Phase I Trial at Moffitt Cancer Center
PR-M03-22-17
Cancer Research
Inceptor Bio Launches Next-Generation CAR-T, CAR-M, and NK/NKT Platform Focused on Advancing Cell and Gene Therapies to Cure Difficult-To-Treat Cancers
PR-M06-21-018
FDA Approval
Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancer
PR-M11-20-027
Endocannabinoid System
Realizing the Promise of Therapeutics Targeting the Endocannabinoid System
PAP-Q3-20-CL-005
Peptide Drugs
Transforming the Treatment of Ocular Diseases and Cancer with Peptide Drugs
PAP-Q3-20-CL-006
Chronokines
Delivering Breakthrough Medicines for Rare Hematologic Diseases and Cancers
PAP-Q2-20-CL-003
Cancer Therapies
Computational Discoveries for Clinical Development of Novel Cancer Therapies
PAP-Q2-20-CL-014
Immunotherapy
Using a Natural Molecular Warning System to Fight Cancer and Infectious Diseases
PAP-Q2-20-CL-020
Cancer and Neurodegenerative Diseases
Leveraging the Cell Cytoskeleton for the Treatment of Cancer and Neurodegenerative Diseases
PAP-Q2-20-CL-024
FDA Approval
Eisai And Merck Announce FDA Approval Of LENVIMA® (lenvatinib) Capsules For First-line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)
PR-M09-18-NI-070
FDA Approval
Sirnaomics Oncology IND Receives Green Light from US FDA to Initiate Study for Treatment of Cholangiocarcinoma
PR-M09-18-NI-062
Approval
Trovagene Receives USAN Approval for "Onvansertib" as Nonproprietary Name for First-in-Class, 3rd Generation PLK1 Inhibitor Drug Candidate, PCM-075
PR-M09-18-NI-048
Oncology
GeneNews and LifeX™ Partner to Deliver Proprietary "Liquid Biopsy" Molecular Diagnostics to Health Systems to Detect Cancer at Earliest Stages
PR-M09-18-NI-047
Oncology
CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study
PR-M09-18-NI-038
Clinical Data
ArQule Announces Publication of Preclinical Data for ARQ 531, a Reversible Inhibitor of Both Wild Type and Mutant BTK
PR-M09-18-NI-027
FDA Approval
Sesen Bio Announces Vicinium Granted Fast Track Designation by FDA for Treatment of Non-Muscle Invasive Bladder Cancer
PR-M08-18-NI-099
Cancer Treatment
OncoPep Announces a Phase 1b Clinical Trial of Its Multi-Peptide Cancer Vaccine PVX-410 in Combination with Citarinostat for Smoldering Multiple Myeloma
PR-M08-18-NI-084
Collaboration
Regeneron and bluebird bio Announce Collaboration to Discover, Develop and Commercialize New Cell Therapies for Cancer
PR-M08-18-NI-054
